{"id":"treatment-d","rwe":[{"pmid":"41806279","year":"2026","title":"Inhaled Corticosteroid/Long-Acting β(2)-Agonist Selection for Patients with Moderate-to-Severe Asthma: Considerations for Real-World Practice, A Narrative Review.","journal":"Advances in therapy"},{"pmid":"41529924","year":"2026","title":"Correlation of Tumor Absorbed Dose with Progression-Free Survival in Metastatic Castration-Resistant Prostate Cancer Treated with (177)Lu-PSMA.","journal":"Journal of nuclear medicine technology"},{"pmid":"41469556","year":"2025","title":"Effect of the Addition of Xianglian Granules to PD-1 Monoclonal Antibodies in Pancancer Patients.","journal":"Biological procedures online"},{"pmid":"40664163","year":"2025","title":"Baseline D-dimers as predictive marker of efficacy of cemiplimab treatment in cutaneous squamous cell carcinoma.","journal":"European journal of cancer (Oxford, England : 1990)"},{"pmid":"39823789","year":"2025","title":"Tissue factor-bearing extracellular vesicles, procoagulant phospholipids and D-dimer as potential biomarkers for venous thromboembolism in patients with newly diagnosed multiple myeloma: A comprehensive analysis.","journal":"Thrombosis research"}],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT04919122","NCT03424005","NCT06918002","NCT01243151","NCT03400254","NCT03205267","NCT00263328","NCT05911295","NCT00736528","NCT00407797","NCT02767089","NCT02078752","NCT06698796","NCT03439514","NCT02319148","NCT00867087","NCT00766116","NCT01247311","NCT00619619","NCT07172321","NCT01964326","NCT00802854","NCT03472573","NCT00482170","NCT05208762"],"aliases":[],"patents":[],"pricing":[],"allNames":"treatment d","offLabel":[],"timeline":[{"date":"2006","type":"neutral","milestone":"Phase 1 Initiated","description":"Phase 1 trial (The Dose Response of Prednisone on Biochemical and Clinical Makers in Adult Healthy Volunteers) — Healthy Adults"},{"date":"2009","type":"neutral","milestone":"Phase 3 Initiated","description":"Phase 3 trial (Compare Perceptions and Satisfaction for Two Different Delivery Mechanisms for Etanercept) — Psoriasis"},{"date":"2009","type":"negative","milestone":"Phase 4 Initiated","description":"Phase 4 trial (Pregabalin In Partial Seizures (PREPS): An Open-Label, Multicenter Add On Therapy Trial) — Partial Seizures. Trial terminated early."},{"date":"2009","type":"neutral","milestone":"Phase 2 Initiated","description":"Phase 2 trial (Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Child And A) — Depression"}],"aiSummary":"I cannot provide a summary as the FDA mechanism text and approved indication information for Treatment D are missing from your request. Please provide the mechanism of action and approved indication to generate an accurate clinical summary.","brandName":"Treatment D","companyId":"pfizer","ecosystem":[],"mechanism":{"target":"","novelty":"","modality":"","drugClass":"Single 875 mg dose of mevrometostat alternative tablet formulation","explanation":"","oneSentence":"Single 875 mg dose of mevrometostat alternative tablet formulation","technicalDetail":""},"commercial":null,"references":[],"biosimilars":[],"companyName":"Pfizer Inc.","competitors":[],"genericName":"treatment-d","indications":{"approved":[],"offLabel":[],"pipeline":[{"name":"Healthy","phase":"discontinued","trialId":"","patients":null,"diseaseId":"unknown","trialName":"","primaryEndpoint":"","expectedCompletion":""}]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT04919122","phase":"discontinued","title":"Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell Carcinoma","status":"discontinued","sponsor":"Duke University","isPivotal":false,"enrollment":468,"indication":"Metastatic Renal Cell Carcinoma","completionDate":"2026-12","primaryEndpoint":"ODYSSEY RCC is a prospective, observational Phase IV study is to understand the cancer management and health-related quality of life in patients with mRCC in routine real-world clinical practice in th"},{"nctId":"NCT03424005","phase":"discontinued","title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metas","status":"discontinued","sponsor":"Hoffmann-La Roche","isPivotal":false,"enrollment":792,"indication":"Metastatic Breast Cancer","completionDate":"2030-09","primaryEndpoint":"This is an umbrella study evaluating the efficacy and safety of multiple treatment combinations in participants with metastatic or inoperable locally advanced breast cancer."},{"nctId":"NCT06918002","phase":"discontinued","title":"Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After ","status":"discontinued","sponsor":"Intergroupe Francophone du Myelome","isPivotal":false,"enrollment":824,"indication":"Multiple Myeloma, Newly Diagnosed","completionDate":"2036-05","primaryEndpoint":"This study is designed as a multicenter, randomized, parallel groups, open-label, phase 3 study in subjects with untreated newly diagnoses Multiple Myeloma eligible for ASCT."},{"nctId":"NCT01243151","phase":"discontinued","title":"Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolem","status":"discontinued","sponsor":"Pfizer","isPivotal":false,"enrollment":68,"indication":"Hypercholesterolemia","completionDate":"2011-10","primaryEndpoint":"The primary objective of this study is to evaluate the safety and tolerability of repeated doses of PF-04950615 (RN316) in study volunteers with hypercholesterolemia."},{"nctId":"NCT03400254","phase":"discontinued","title":"Gedatolisib, Hydroxychloroquine or the Combination for Prevention of Recurrent Breast Cancer (\"GLACI","status":"discontinued","sponsor":"Abramson Cancer Center at Penn Medicine","isPivotal":false,"enrollment":0,"indication":"Breast Cancer","completionDate":"2019-08","primaryEndpoint":"This clinical trial will assess the safety and early efficacy of the role of gedatolisib and hydroxychloroquine in early-stage breast cancer patients with residual disease and evidence of disseminated"},{"nctId":"NCT03205267","phase":"discontinued","title":"Phase II Study Testing the Tolerability and the Efficacy of Bosutinib in Chronic Phase CML Patients","status":"discontinued","sponsor":"University of Bonn","isPivotal":false,"enrollment":127,"indication":"Chronic Myelogenous Leukaemia","completionDate":"2019-10","primaryEndpoint":"Bosutinib is a 2nd generation tyrosine kinase inhibitor that has shown promising results from first up to fourth line treatment in patients with in chronic phase of chronic myelogenous leukaemia."},{"nctId":"NCT00263328","phase":"discontinued","title":"Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidne","status":"discontinued","sponsor":"Pfizer","isPivotal":false,"enrollment":46,"indication":"Kidney Transplantation","completionDate":"2014-01","primaryEndpoint":"A new immunosuppressive drug, based on the inhibition of an important enzyme in the immune system called JAK3, is being developed by Pfizer to prevent transplant rejection."},{"nctId":"NCT05911295","phase":"discontinued","title":"Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expre","status":"discontinued","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","isPivotal":false,"enrollment":412,"indication":"Urothelial Carcinoma","completionDate":"2026-06","primaryEndpoint":"This study will enroll participants with urothelial cancer (UC)."},{"nctId":"NCT00736528","phase":"discontinued","title":"A Phase I, Multiple Dose Study of PF-04447943 in Healthy Elderly Volunteers","status":"discontinued","sponsor":"Pfizer","isPivotal":false,"enrollment":10,"indication":"Healthy","completionDate":"2008-09","primaryEndpoint":"To describe the safety, tolerability and pharmacokinetics of PF-04447943 after administration of multiple, ascending, oral doses to healthy elderly subjects."},{"nctId":"NCT00407797","phase":"discontinued","title":"Pregabalin In Partial Seizures (PREPS): An Open-Label, Multicenter Add On Therapy Trial","status":"discontinued","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","isPivotal":false,"enrollment":136,"indication":"Partial Seizures","completionDate":"2009-08","primaryEndpoint":"The purpose of this study is to assess the clinical improvement by partial seizures reduction, safety and tolerability of subjects having partial epilepsy related to the adjunction of pregabalin BID ("},{"nctId":"NCT02767089","phase":"discontinued","title":"The Dose Response of Prednisone on Biochemical and Clinical Makers in Adult Healthy Volunteers","status":"discontinued","sponsor":"Pfizer","isPivotal":false,"enrollment":37,"indication":"Healthy Adults","completionDate":"2006-03","primaryEndpoint":"The purpose of this study is to further access the utility of biochemical and clinical biomarkers for glucocorticoid-mediated anti-inflammatory effects and safety endpoints against which dissociated a"},{"nctId":"NCT02078752","phase":"discontinued","title":"A Study Of PF-06647263 In Patients With Advanced Solid Tumors","status":"discontinued","sponsor":"Pfizer","isPivotal":false,"enrollment":60,"indication":"Neoplasms","completionDate":"2017-05","primaryEndpoint":"To assess the safety and tolerability at increasing dose levels of PF-06647263 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase "},{"nctId":"NCT06698796","phase":"discontinued","title":"A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory","status":"discontinued","sponsor":"Pfizer","isPivotal":false,"enrollment":211,"indication":"Dermatomyositis","completionDate":"2027-11","primaryEndpoint":"The purpose of this study is to understand how the study medicine, dazukibart, works in people with active idiopathic inflammatory myopathies (dermatomyositis \\[DM\\] or polymyositis \\[PM\\])."},{"nctId":"NCT03439514","phase":"discontinued","title":"A Study of ARRY-371797 (PF-07265803) in Patients With Symptomatic Dilated Cardiomyopathy Due to a La","status":"discontinued","sponsor":"Pfizer","isPivotal":false,"enrollment":77,"indication":"Dilated Cardiomyopathy","completionDate":"2022-10","primaryEndpoint":"This is a randomized, double-blind, placebo-controlled study in patients with dilated cardiomyopathy (DCM) due to a mutation of the gene encoding the lamin A/C protein (LMNA)."},{"nctId":"NCT02319148","phase":"discontinued","title":"A Study to Estimate the Effect of CYP3A4 Inhibitors (Itraconazole, Diltiazem or Verapamil) on the Ph","status":"discontinued","sponsor":"Pfizer","isPivotal":false,"enrollment":22,"indication":"Healthy Volunteers","completionDate":"2014-10","primaryEndpoint":"The primary objective of the study is to estimate the effects of different strong enzyme (CYP3A4) inhibitors, itraconazole, diltiazem, or verapamil on the single dose pharmacokinetics of PF-00489791 i"},{"nctId":"NCT00867087","phase":"discontinued","title":"Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin'","status":"discontinued","sponsor":"Pfizer","isPivotal":false,"enrollment":64,"indication":"Lymphoma, B-Cell","completionDate":"2012-10","primaryEndpoint":"The purpose of this study is to evaluate inotuzumab ozogamicin in combination with rituximab prior to an autologous stem cell transplant (aSCT) in patients with relapsed/refractory diffuse large B-cel"},{"nctId":"NCT00766116","phase":"discontinued","title":"Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid ","status":"discontinued","sponsor":"University of California, San Diego","isPivotal":false,"enrollment":50,"indication":"Acute Myeloid Leukemia","completionDate":"2014-09","primaryEndpoint":"This study will test an experimental combination of the drugs Mylotarg and 5-azacitidine in the hopes of finding a treatment that may be effective against Acute Myeloid Leukemia that has come back aft"},{"nctId":"NCT01247311","phase":"discontinued","title":"Vitamin D and the Health of Blood Vessels in Kidney Disease","status":"discontinued","sponsor":"University of British Columbia","isPivotal":false,"enrollment":129,"indication":"Chronic Kidney Disease (CKD)","completionDate":"2014-08","primaryEndpoint":"Individuals with kidney disease have a high risk of heart disease."},{"nctId":"NCT00619619","phase":"discontinued","title":"Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Child And A","status":"discontinued","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","isPivotal":false,"enrollment":59,"indication":"Depression","completionDate":"2009-11","primaryEndpoint":"The primary purpose of this study is to test the safety and tolerability of single ascending doses of Desvenlafaxine Succinate Sustained-Release (DVS SR) in both child and adolescent outpatients with "},{"nctId":"NCT07172321","phase":"discontinued","title":"A Study to Learn How Different Forms of the Study Medicine Called PF 08049820 Are Taken up Into the ","status":"discontinued","sponsor":"Pfizer","isPivotal":false,"enrollment":12,"indication":"Atopic Dermatitis","completionDate":"2025-10","primaryEndpoint":"The purpose of this study is to see how different forms of a medicine called PF-08049820 move through the body when taken by mouth."},{"nctId":"NCT01964326","phase":"discontinued","title":"Actual Use Trial of Atorvastatin Calcium 10 mg","status":"discontinued","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","isPivotal":false,"enrollment":1311,"indication":"Hypercholesterolemia","completionDate":"2014-12","primaryEndpoint":"The purpose of this actual use study is to simulate the over the counter use of atorvastatin calcium 10 mg."},{"nctId":"NCT00802854","phase":"discontinued","title":"Post Marketing Surveillance Study To Observe Safety And Efficacy Of Eraxis® IV","status":"discontinued","sponsor":"Pfizer","isPivotal":false,"enrollment":244,"indication":"Candidemia","completionDate":"2016-05","primaryEndpoint":"The objective of this study is to collect the safety and efficacy data of Eraxis IV (anidulafungin) 100 mg according to Korea Ministry of Food and Drug Safety regulations."},{"nctId":"NCT03472573","phase":"discontinued","title":"Palbociclib and Dexamethasone in Treating Participants With Relapsed or Refractory B-Cell Acute Lymp","status":"discontinued","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","isPivotal":false,"enrollment":7,"indication":"Recurrent B Acute Lymphoblastic Leukemia","completionDate":"2021-08","primaryEndpoint":"This phase I trial studies the side effects and best dose of palbociclib when given together with dexamethasone in treating participants with B-cell acute lymphoblastic leukemia that has come back aft"},{"nctId":"NCT00482170","phase":"discontinued","title":"Compare Perceptions and Satisfaction for Two Different Delivery Mechanisms for Etanercept","status":"discontinued","sponsor":"Pfizer","isPivotal":false,"enrollment":421,"indication":"Psoriasis","completionDate":"2009-04","primaryEndpoint":"Primary objective of this study is to compare patient satisfaction with the prefilled syringe (PFS) and the auto-injector (AI), two different delivery devices for etanercept after 12 weeks of use, usi"},{"nctId":"NCT05208762","phase":"discontinued","title":"A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors","status":"discontinued","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","isPivotal":false,"enrollment":714,"indication":"Carcinoma, Non-Small-Cell Lung","completionDate":"2028-01","primaryEndpoint":"This study will test the safety of a drug called PF-08046054/SGN-PDL1V alone and with pembrolizumab in participants with solid tumors."}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Other"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"","enrichmentLevel":3,"visitCount":3,"trialStats":{"total":13,"withResults":3},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}